Skip to main content
Erschienen in: World Journal of Surgery 2/2015

01.02.2015 | Original Scientific Report

Implementation of a Standardized HIPEC Protocol Improves Outcome for Peritoneal Malignancy

verfasst von: Anke M. J. Kuijpers, Arend G. J. Aalbers, Simon W. Nienhuijs, Ignace H. J. T. de Hingh, Marinus J. Wiezer, Bert van Ramshorst, Robert J. van Ginkel, Klaas Havenga, Wilma D. Heemsbergen, Michael Hauptmann, Victor J. Verwaal

Erschienen in: World Journal of Surgery | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Experience with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a pioneer hospital resulted in a treatment protocol that has become the standard in the Netherlands. Outcome of CRS and HIPEC was reviewed to assure differences between the pioneer phase and the period wherein the Dutch HIPEC protocol was clinically implemented.

Methods

The first consecutive 100 CRS and HIPEC procedures performed in the Netherlands were included as pioneer cohort (1995–1999). Two-hundred and seventy-two procedures that were performed in three participating HIPEC centres after the implementation of the Dutch HIPEC protocol were included as the implementation cohort (2005–2012). Another 100 recent patients of the first centre were included as a control group (2009–2011). Indications for the CRS and HIPEC treatment were peritoneal carcinomatosis (PC) from colorectal carcinoma and pseudomyxoma peritonei (PMP).

Results

Of the 472 included procedures, 327 (69 %) procedures were performed for PC from colorectal carcinoma and 145 for PMP (31 %). Compared with the implementation phase, the pioneer phase was characterized by more affected abdominal regions (mean 4.3 vs. 3.5, p < 0.001), more resections (mean 3.8 vs. 3.4, p < 0.001), less macroscopic radical cytoreductions (66 vs. 86 %, p < 0.001) and more patients with major morbidity (grade III–V) (64 vs. 32 %, p < 0.001). Other determinants of morbidity were high tumour load and multiple organ resections. Outcome of the implementation phase was similar to the control group.

Conclusions

This study determined that outcome had improved ever since the Dutch HIPEC protocol has been implemented based on completeness of cytoreduction and decreasing morbidity.
Literatur
1.
Zurück zum Zitat Verwaal VJ, van Ruth S, Witkamp A et al (2005) Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg 12(1):9–12CrossRef Verwaal VJ, van Ruth S, Witkamp A et al (2005) Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg 12(1):9–12CrossRef
2.
Zurück zum Zitat Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27(5):681–685PubMedCrossRef Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27(5):681–685PubMedCrossRef
3.
Zurück zum Zitat Elias D, Glehen O, Pocard M et al (2010) A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 251(5):896–901PubMedCrossRef Elias D, Glehen O, Pocard M et al (2010) A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 251(5):896–901PubMedCrossRef
4.
Zurück zum Zitat Glehen O, Gilly FN, Boutitie F et al (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618PubMedCrossRef Glehen O, Gilly FN, Boutitie F et al (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618PubMedCrossRef
5.
Zurück zum Zitat Verwaal VJ, Bruin S, Boot H et al (2008) 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432PubMedCrossRef Verwaal VJ, Bruin S, Boot H et al (2008) 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432PubMedCrossRef
6.
Zurück zum Zitat Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7:5PubMedCentralPubMedCrossRef Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7:5PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Lautman L, Gallimore P (1987) Control of the crew caused accident: results of a 12-operator survey. Boeing Airliner April-June:1–6 Lautman L, Gallimore P (1987) Control of the crew caused accident: results of a 12-operator survey. Boeing Airliner April-June:1–6
8.
Zurück zum Zitat Kianmanesh R, Scaringi S, Sabate J-M et al (2007) Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 245(4):597–603PubMedCentralPubMedCrossRef Kianmanesh R, Scaringi S, Sabate J-M et al (2007) Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 245(4):597–603PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Esquivel J, Sticca R, Sugarbaker P et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement society of surgical oncology. Ann Surg Oncol 14(1):128–133PubMedCrossRef Esquivel J, Sticca R, Sugarbaker P et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement society of surgical oncology. Ann Surg Oncol 14(1):128–133PubMedCrossRef
11.
Zurück zum Zitat Witkamp AJ, De Bree E, van Goethem AR et al (2002) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27(6):365–374CrossRef Witkamp AJ, De Bree E, van Goethem AR et al (2002) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27(6):365–374CrossRef
12.
Zurück zum Zitat Verwaal VJ, Van Tinteren H, Van Ruth S et al (2004) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91(6):739–746PubMedCrossRef Verwaal VJ, Van Tinteren H, Van Ruth S et al (2004) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91(6):739–746PubMedCrossRef
13.
Zurück zum Zitat Younan R, Kusamura S, Baratti D et al (2008) Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 98(4):253–257PubMedCrossRef Younan R, Kusamura S, Baratti D et al (2008) Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 98(4):253–257PubMedCrossRef
14.
Zurück zum Zitat Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12(3):585–603PubMedCrossRef Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12(3):585–603PubMedCrossRef
15.
Zurück zum Zitat Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456PubMedCrossRef Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456PubMedCrossRef
16.
Zurück zum Zitat Chua TC, Yan TD, Smigielski ME et al (2009) Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 16(7):1903–1911PubMedCrossRef Chua TC, Yan TD, Smigielski ME et al (2009) Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 16(7):1903–1911PubMedCrossRef
17.
Zurück zum Zitat Smeenk RM, Verwaal VJ, Antonini N et al (2007) Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245(1):104–109PubMedCentralPubMedCrossRef Smeenk RM, Verwaal VJ, Antonini N et al (2007) Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245(1):104–109PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92(1):85–91PubMedCrossRef Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92(1):85–91PubMedCrossRef
19.
Zurück zum Zitat Elias D, Honoré C, Dumont F et al (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254(2):289–293PubMedCrossRef Elias D, Honoré C, Dumont F et al (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254(2):289–293PubMedCrossRef
20.
Zurück zum Zitat Kusamura S, Baratti D, Deraco M (2012) Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 255(2):348–356PubMedCrossRef Kusamura S, Baratti D, Deraco M (2012) Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 255(2):348–356PubMedCrossRef
21.
Zurück zum Zitat Jaehne J (2009) Cytoreductive procedures-strategies to reduce postoperative morbidity and management of surgical complications with special emphasis on anastomotic leaks. J Surg Oncol 100(4):302–305PubMedCrossRef Jaehne J (2009) Cytoreductive procedures-strategies to reduce postoperative morbidity and management of surgical complications with special emphasis on anastomotic leaks. J Surg Oncol 100(4):302–305PubMedCrossRef
22.
Zurück zum Zitat Spiliotis JD, Halkia EA, Efstathiou E (2011) Peritoneal carcinomatosis 2011; it’s about time for chemosurgery. J BUON 16(3):400–408PubMed Spiliotis JD, Halkia EA, Efstathiou E (2011) Peritoneal carcinomatosis 2011; it’s about time for chemosurgery. J BUON 16(3):400–408PubMed
23.
Zurück zum Zitat Kusamura S, Dominique E, Baratti D et al (2008) Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 98(4):247–252PubMedCrossRef Kusamura S, Dominique E, Baratti D et al (2008) Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 98(4):247–252PubMedCrossRef
24.
Zurück zum Zitat Stephens AD, Alderman R, Chang D et al (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6(8):790–796PubMedCrossRef Stephens AD, Alderman R, Chang D et al (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6(8):790–796PubMedCrossRef
25.
Zurück zum Zitat Elias D (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267–272PubMedCrossRef Elias D (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267–272PubMedCrossRef
26.
Zurück zum Zitat Hompes D, D’Hoore A, Cutsem E et al (2012) The Treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a belgian multicentre prospective phase II clinical study. Ann Surg Oncol 19(7):2186–2194PubMedCrossRef Hompes D, D’Hoore A, Cutsem E et al (2012) The Treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a belgian multicentre prospective phase II clinical study. Ann Surg Oncol 19(7):2186–2194PubMedCrossRef
Metadaten
Titel
Implementation of a Standardized HIPEC Protocol Improves Outcome for Peritoneal Malignancy
verfasst von
Anke M. J. Kuijpers
Arend G. J. Aalbers
Simon W. Nienhuijs
Ignace H. J. T. de Hingh
Marinus J. Wiezer
Bert van Ramshorst
Robert J. van Ginkel
Klaas Havenga
Wilma D. Heemsbergen
Michael Hauptmann
Victor J. Verwaal
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
World Journal of Surgery / Ausgabe 2/2015
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2801-y

Weitere Artikel der Ausgabe 2/2015

World Journal of Surgery 2/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.